A phase i open-label study to identify a dosing regimen of the pan-akt inhibitor azd5363 for evaluation in solid tumors and in pik3ca-mutated breast and gynecologic cancers

Clinical Cancer Research

Volumn 24, Issue 9, 2018, Pages 2050-2059

  Banerji, Udai ^a   Dean, Emma J ^b   Alejandro Perez Fidalgo, J ^c   Batist, Gerald ^d   Bedard, Philippe L ^e   You, Benoit ^f   Westin, Shannon N ^g   Kabos, Peter ^h   Garrett, Michelle D ⁱ   Tall, Mathew ^a   Ambrose, Helen ^j   Carl Barrett, J ^j   Hedley Carr, T ^j   Amy Cheung, S Y ^j   Corcoran, Claire ^j   Cullberg, Marie ^j   Davies, Barry R ^j   de Bruin, Elza C ^j   Elvin, Paul ^j   Foxley, Andrew ^j   Lawrence, Peter ^j   Lindemann, Justin P O ^j   Maudsley, Rhiannon ^j   Pass, Martin ^j   Rowlands, Vicky ^j   Rugman, Paul ^j   Schiavon, Gaia ^j   Yates, James ^j   Schellens, Jan H M ^k,l   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d MCGILL UNIVERSITY   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f UNIVERSITÉ LYON 1   (France)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h UNIVERSITY OF COLORADO CANCER CENTER   (United States)

ⁱ UNIVERSITY OF KENT   (United Kingdom)

^j ASTRAZENECA   (United Kingdom)

^k NETHERLANDS CANCER INSTITUTE   (Netherlands)

^l UTRECHT UNIVERSITY   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPIVASERTIB; 4-AMINO-N-(1-(4-CHLOROPHENYL)-3-HYDROXYPROPYL)-1-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)PIPERIDINE-4-CARBOXAMIDE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; TUMOR MARKER;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SIZE; CHRONIC DISEASE; COHORT ANALYSIS; COLON CANCER; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEMALE GENITAL TRACT CANCER; GENE; GENE MUTATION; HUMAN; HYPERGLYCEMIA; LUNG CANCER; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MINIMUM PLASMA CONCENTRATION; MUTATIONAL ANALYSIS; NAUSEA; OPEN STUDY; OVARY CANCER; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PIK3CA GENE; PLEURA CANCER; PRIORITY JOURNAL; RASH; RECTUM CANCER; SOLID MALIGNANT NEOPLASM; TIME TO MAXIMUM PLASMA CONCENTRATION; UTERINE CERVIX CANCER; WORLD HEALTH ORGANIZATION; AGED; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; FEMALE GENITAL TRACT TUMOR; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; MUTATION; PATHOLOGY; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; AREA UNDER CURVE; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 85045540606     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-2260     Document Type: Article

References (29)

1. Brown JS, Banerji U. Maximising the potential of AKT inhibitors as anticancer treatments. Pharmacol Ther 2017;172:101–15.
2. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005;24:7455–64.
3. Davies BR, Greenwood H, Dudley P, Crafter C, Yu DH, Zhang J, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol Cancer Ther 2012;11:873–87.
4. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, et al. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 2013;73:276–84.
5. Li J, Davies BR, Han S, Zhou M, Bai Y, Zhang J, et al. The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere. J Transl Med 2013;11:241.
6. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 2011;10:558–65.
7. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2014;138:241–56.
8. AstraZeneca. Global policy: bioethics. 2015. Cambridge (UK): AstraZeneca; Available from: https://www.astrazeneca.com/content/dam/az/PDF/Bioethics_policy.pdf.
9. Tamura K, Hashimoto J, Tanabe Y, Kodaira M, Yonemori K, Seto T, et al. Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2016;77:787–95.
10. Elvin P, Palmer A, Womack C, Tall M, Swales KE, Garrett MD, et al. Pharmacodynamic activity of the AKT inhibitor AZD5363 in patients with advanced solid tumors. J Clin Oncol 2014;32(15S):abstr 2541.
11. Yates JW, Dudley P, Cheng J, D'Cruz C, Davies BR. Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363. Cancer Chemother Pharmacol 2015;76:343–56.
12. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, et al. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res 2015;21:739–48.
13. Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodriguez O, et al. Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. Clin Cancer Res 2013;19:6976–86.
14. Yan Y, Wagle M-C, Punnoose E, Musib L, Budha N, Nannini KL, et al. A first-in-human trial of GDC-0068: a novel, oral, ATP-competitive Akt inhibitor, demonstrates robust suppression of teh Akt pathway in surrogate and tumour tissues. Mol Cancer Ther 2011;10(11 Suppl):abstr B154.
15. Burris HA, Siu LL, Infante JR, Wheler JJ, Kurkjian C, Opalinska J, et al. Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase 1 first-in-human study. J Clin Oncol 2011;29(suppl):abstr 3003.
16. Saura C, Roda D, Rosello S, Oliveira M, Macarulla T, Perez-Fidalgo JA, et al. A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors. Cancer Discov 2017;7:102–13.
17. Hage HR, Bourron O, Hajduch E. Defect of insulin signal in peripheral tissues: important role of ceramide. World J Diabetes 2014;5: 244–57.
18. Banerji U, Workman P. Critical parameters in targeted drug development: the pharmacological audit trail. Semin Oncol 2016;43:436–45.
19. Dupont JJ, Laenkholm AV, Knoop A, Ewertz M, Bandaru R, Liu W, et al. PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res 2011;17: 667–77.
20. Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res 2012;18:3462–9.
21. Yap TA, Bjerke L, Clarke PA, Workman P. Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol 2015; 23:98–107.
22. Leighl NB, Dent S, Clemons M, Vandenberg TA, Tozer R, Warr DG, et al. A Phase 2 study of perifosine in advanced or metastatic breast cancer. Breast Cancer Res Treat 2008;108:87–92.
23. National Cancer Institute. Akt inhibitor MK2206 in treating patients with advanced breast cancer. 2016. Bethesda (MD): US National Library of Medicine; Available from: https://clinicaltrials.gov/ct2/show/results/NCT01277757?sect¼X70156&term¼nct01277757&rank¼1#outcome1.
24. Konstantinopoulos P, Makker V, BArry WT, Liu J, Horowitz NS, Birrer NJ, et al. Phase II, single stage, cohort expansion study of MK-2206 in recurrent endometrial serous cancer. J Clin Oncol 2014;32(5s):abstr 5515.
25. Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, et al. AKT inhibition in solid tumors with AKT1 mutations. J Clin Oncol 2017;35:2251–9.
26. Al-Lazikani B, Banerji U, Workman P. Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol 2012;30:679–92.
27. Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520–9.
28. Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, et al. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009;27:4536–41.
29. Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol 2016;14:57–66.